Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Aug;382(2):103-8.
doi: 10.1007/s00210-010-0529-2. Epub 2010 Jun 3.

Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges

Editorial

Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges

Martin C Michel et al. Naunyn Schmiedebergs Arch Pharmacol. 2010 Aug.

Abstract

As β3-adrenoceptor agonists metamorphose from experimental tools into therapeutic drugs, it is vital to obtain a comprehensive picture of the cell and tissue functions mediated by this receptor subtype in humans. Human tissues with proven functions and/or a high expression of β3-adrenoceptors include the urinary bladder, the gall bladder, and other parts of the gastrointestinal tract. While several other β3-adrenoceptor functions have been proposed based on results obtained in animals, their relevance to humans remains uncertain. For instance, β3-adrenoceptors perform an important role in thermogenesis and lipolysis in rodent brown and white adipose tissue, respectively, but their role in humans appears less significant. Moreover, the use of tools such as the agonist BRL 37344 and the antagonist SR59230A to demonstrate functional involvement of β3-adrenoceptors may lead in many cases to misleading conclusions as they can also interact with other β-adrenoceptor subtypes or even non-adrenoceptor targets. In conclusion, we propose that many responses attributed to β3-adrenoceptor stimulation may need re-evaluation in the light of the development of more selective tools. Moreover, findings in experimental animals need to be extended to humans in order to better understand the potential additional indications and side effects of the β3-adrenoceptor agonists that are beginning to enter clinical medicine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Aizawa N, Igawa Y, Nishizawa O, Wyndaele J-J (2010) Effects of CL316,243, a beta3-adrenoceptor agonist, and intravesical prostaglandin E2 on the primary bladder afferent activity of the rat. Neurourol Urodyn in press - PubMed
    1. Arch JRS. Perspectives from β3-adrenoceptor agonists on pharmacology, physiology and obesity drug discovery. Naunyn-Schmiedeberg's Arch Pharmacol. 2008;378:225–240. doi: 10.1007/s00210-008-0271-1. - DOI - PubMed
    1. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984;309:163–165. doi: 10.1038/309163a0. - DOI - PubMed
    1. Arner P, Kriegholm E, Engfeldt P. In vivo interactions between beta-1 and beta-2 adrenoceptors regulate catecholamine tachyphylaxia in human adipose tissue. J Pharmacol Exp Ther. 1991;259:317–323. - PubMed
    1. Atef N, Lafontan M, Double A, Helary C, Ktorza A, Penicaud L. A specific β3-adrenoceptor agonist induces pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol. 1996;298:287–292. doi: 10.1016/0014-2999(95)00802-0. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources